AMED Liaison Committee on Infectious Disease Drug Discovery and Drug Discovery Industry-Academia-Government has opened its website.
May 11, 2022
The AMED Infectious Diseases Drug Discovery Industry-Academia-Government Liaison Committee was established in September 2018 to further promote industry-academia-government collaboration in drug discovery research and development in the field of infectious diseases, with the Japan Agency for Medical Research and Development (AMED), academic societies (the Japan Infectious Diseases Society, the Japan Chemotherapy Society, the Joint Study Committee of Seven Societies for the Promotion of Therapy and Drug Discovery in Infectious Diseases), and pharmaceutical companies (the Japan Pharmaceutical Manufacturers Association) playing a central role. It was established in September 2018 with the aim of further promoting industry-academia-government collaboration in drug discovery research and development in the field of infectious diseases.
A website introducing the activities of the Liaison Committee is now available, please click on the link below.
AMED Infectious Disease Drug Discovery Industry-Academia-Government Liaison Group
The first edition of the Japanese version of the Priority Pathogen List (PPL) (March 2021), which was created by JPMA members as a list of pathogens to be targeted in AMR drug discovery research, has also been released and is expected to become an important list for planning drug resistance measures in Japan. The list is expected to become an important list for planning drug resistance countermeasures in Japan.